Hematologic MalignancyHemoDiagNCT02134574
Prospective Cohort With Hemopathy in Languedoc-Roussillon
An observational study of Hematologic Malignancy, run by University Hospital, Montpellier at 1 site in France.
Trial summary
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematologic Malignancy
- What is being tested?
- hematologic malignancy
- How many people
- 500 participants
- Where
- 1 siteFrance
- Study dates
- Feb 2014to Jun 2033
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patient for suspected haematological disease and justifying further exploration
Who may be able to join
- Age over 18
- Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
- Having signed an informed consent
- Affiliated with a social security scheme
Who cannot join
- Minor or major protected
- Patients who have received treatment for hematological pathology
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Valerie ROUILLE contact
France1 site, 1 recruiting
- Recruiting
Hematology department - UHMontpellier Saint éloi
Montpellier
Valerie ROUILLE, v-rouille@chu-montpellier.fr
GUILLAUME CARTRON
About this study
Official title: Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Read the detailed description
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.
- Conditions
- Hematologic Malignancy
- Being tested
- hematologic malignancy
- Keywords
- Lymphoma,, leukemia,, multiple myeloma,, hodgkin disease
- Medical subject headings
- Hematologic Neoplasms, Lymphoma, Leukemia, Multiple Myeloma, Hodgkin Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
hematologic malignancyBiological
Also called hematologic malignancy with a sampling of blood
hematologic malignancy with a sampling of blood
| Study group | Role | What they receive |
|---|---|---|
| hematologic malignancy | hematologic malignancy with a sampling of blood Receives: Biological: hematologic malignancy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival with 2 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
Measured: 2 years
Secondary outcomes (2)
Survival with 5 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
Measured: 5 years
Survival with 10 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2014 (estimated)
- Study startFeb 2014
- Primary completionJun 2033 (estimated)
- Study completionJun 2033 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic MalignancyStudies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- GUILLAUME CARTRON, Principal investigator, University Hospital, Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02134574
- Sponsor's protocol ID
- 9011
- Acronym
- HemoDiag
- Status last verified
- Jun 2026
- First submitted
- 22 Apr 2014
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon
- ClinicalTrials.gov ID
- NCT02134574
- Acronym / sponsor ID
- HemoDiag / 9011
- Conditions
- Hematologic Malignancy
- Keywords
- Lymphoma,, leukemia,, multiple myeloma,, hodgkin disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Study start
- Feb 2014
- Primary completion
- Jun 2033 (estimated)
- Study completion
- Jun 2033 (estimated)
- First posted
- 9 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy.
Detailed description
Prospective Cohort Study of clinical and laboratory data of patients with hemopathy in LR.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| hematologic malignancy | – | Biological: hematologic malignancyhematologic malignancy with a sampling of blood |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patient for suspected haematological disease and justifying further exploration
Key inclusion criteria (4 listed)
- Age over 18
- Consultant or hospitalized patient for suspected malignant hemopathy and justifying further exploration or patient with a diagnosis of malignant hemopathy less than 6 months old at the time of signing the consent
- Having signed an informed consent
- Affiliated with a social security scheme
Key exclusion criteria (2 listed)
- Minor or major protected
- Patients who have received treatment for hematological pathology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| hematologic malignancyAlso: hematologic malignancy with a sampling of bloodhematologic malignancy with a sampling of blood | Biological | hematologic malignancy |
Primary outcome
Survival with 2 years
Time frame: 2 years
Prospective Cohort Study of clinical and biological data Analysis Biological, clinical and questionnaire EORTC_QLQ-C30
2 secondary outcomes
Survival with 5 years
Time frame: 5 years
Survival with 10 years
Time frame: 10 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
Related trials for Hematologic Malignancy
RecruitingPhase 1
Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
AML, Multiple Myeloma
RecruitingPhase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Enrolling by invitationObservational study
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Lyphoma, B-Cell, Leukemia, B-cell
Active, not recruitingPhase 1
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Multiple Myeloma
Active, not recruitingPhase 1/2
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Valerie ROUILLE contact
GUILLAUME CARTRON principal investigator
University Hospital, Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic Malignancy, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Valerie ROUILLE (v-rouille@chu-montpellier.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival with 2 years (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.